| Sep 18 |
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
|
| Sep 17 |
Ascendis Challenges BioMarin, But Market Response Seems Excessive
|
| Sep 17 |
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
|
| Sep 17 |
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
|
| Sep 17 |
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
|
| Sep 16 |
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
|
| Sep 16 |
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
|
| Sep 16 |
BioMarin off 17% as Ascendis data seen as threat to Voxzogo
|
| Sep 16 |
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
|
| Sep 16 |
Ascendis Pharma Says Trial of Potential Dwarfism Drug Achieved Primary Endpoint
|
